Back to News
Market Impact: 0.4
Roche: Enicepatide Shows Mean HbA1c Reduction Of 2.65% In Phase II Study At 48 Weeks
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Roche reported positive topline Phase II results for enicepatide (CT-388-104) in adults with type 2 diabetes and overweight or obesity. The drug met both primary endpoints and showed dose-dependent effects, supporting its clinical-development potential in the large diabetes and obesity treatment markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.60
More News
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Why is Celldex Therapeutics stock sliding today?
- Is Regeneron Stock a Bargain Below $800?
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Trump Says US Team Met With Iranians at UNGA